Radiopharm Theranostics Ltd (RADX) Total Non-Current Liabilities (2023 - 2025)
Radiopharm Theranostics (RADX) posted quarterly Total Non-Current Liabilities of $183656.9 for Q2 2025, up 2.81% year-over-year from $178643.7 in Q2 2024, and up 2.81% quarter-over-quarter from $178643.7 in Q2 2024.
Radiopharm Theranostics Ltd (RADX) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has reported Total Non-Current Liabilities for 3 consecutive years, with $183656.9 the latest figure, recorded in Q2 2025.
- In Q2 2025, Total Non-Current Liabilities rose 2.81% year-over-year to $183656.9; the TTM figure through Jun 2025 stood at $183656.9 (up 2.81% YoY), while the FY2025 annual figure was $28.7 million, up 5.79% from the prior year.
- Total Non-Current Liabilities climbed to $183656.9 in Q2 2025 per RADX's latest filing, from $178643.7 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $183656.9 in Q2 2025 and bottomed at -$169202.0 in Q2 2023.
- Historically, Total Non-Current Liabilities has averaged $64366.2 across 3 years, with a median of $178643.7 in 2024.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities surged 205.58% — and 2025, when it increased 2.81%.
- Radiopharm Theranostics' Total Non-Current Liabilities stood at -$169202.0 in 2023, then soared by 205.58% to $178643.7 in 2024, then rose by 2.81% to $183656.9 in 2025.
- Business Quant data shows RADX's Total Non-Current Liabilities at $183656.9 in Q2 2025, $178643.7 in Q2 2024, and -$169202.0 in Q2 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 183,656.95 |
| Jun 30, 2024 | 178,643.67 |
| Jun 30, 2023 | -169,202.00 |